The New Hit Depression Treatment? A Ketamine-Derived Nasal Spray

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual sales last year for its maker, Johnson and Johnson. Further Listening: -A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees.  -America's Maternal Mental Health Crisis  Further Reading: -J&J’s Ketamine-Derived Drug Is Taking Off  -Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.  Learn more about your ad choices. Visit megaphone.fm/adchoices

There are no comments yet.

Please log in to write the first comment.